Publication date: Feb 13, 2025
This study evaluated SARS-CoV-2 infection impacts on clinical characteristics, antibody levels, and immune responses in 100 malignant hematological tumor patients. Laboratory assessments included hematological, biochemical, and inflammatory markers. Multivariable analysis identified age (OR = 1. 56, p = 0. 004), chemotherapy cycles (OR = 1. 86, p
| Concepts | Keywords |
|---|---|
| Chemotherapy | clinical outcomes |
| Hematological | COVID-19 |
| Immune | immune response |
| Laboratory | malignant hematological tumors |
| patients | |
| SARS-CoV-2 |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | SARS-CoV-2 infection |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | tumors |
| disease | IDO | immune response |
Original Article
(Visited 3 times, 1 visits today)